Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals is attractive fundamentally because palazestrant appears differentiated in both ESR1m and ESR1wt disease, addressing a large underserved endocrine-sensitive population where ~35-40% of 2L patients carry ESR1 mutations and current approved 2L+ oral SERDs leave wild-type patients largely untreated. Commercial momentum in the class is also encouraging, as Inluriyo’s worldwide sales reached $75M in 2Q26 and $110M YTD through June, validating payer and physician adoption while still underscoring unmet need that a more effective therapy could capture. Beyond palazestrant, OP-3136 adds pipeline depth with 32 patients enrolled, 19 response-evaluable, 68% tumor shrinkage, 16% PRs, no DLTs or Grade 4/5 TRAEs up to 45 mg QD, supporting a broader, lower-risk growth story.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products, so its valuation rests on uncertain pipeline execution rather than proven commercial cash flow. The outlook is pressured by delayed OPERA-01 topline data, a pushed-out commercialization assumption for palazestrant to 2028, and elevated operating expenses of $67.2M in 2Q26 with full-year 2026 expenses estimated at $269.2M, while the company reported an EPS of ($0.61). Although cash and equivalents of $461.1M should fund operations into 2028, the dependence on binary Phase 3 outcomes, safety risk in combination regimens, and roughly $400M of additional financing needed through 2040 support a negative fundamental view.